HC Wainwright & Co. Reiterates Buy on Viking Therapeutics, Maintains $90 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating on Viking Therapeutics, maintaining a $90 price target. Analyst Joseph Pantginis continues to show confidence in the company's prospects.
October 09, 2024 | 1:51 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating on Viking Therapeutics, maintaining a $90 price target. Analyst Joseph Pantginis continues to show confidence in the company's prospects.
The reiteration of a Buy rating and maintenance of a $90 price target by a reputable analyst can positively influence investor sentiment and potentially lead to a short-term increase in VKTX's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100